Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human platelet alloantigens.

S Santoso1, V Kiefel

  • 1Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig University Giessen, Germany. sentot.santoso@immunologie.med.uni-giessen.de

Wiener Klinische Wochenschrift
|December 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alloimmunization against platelet-specific antigen Dik on glycoprotein IIb in a case of fetal-neonatal alloimmune thrombocytopenia.

Transfusion·2025
Same author

Psychotherapeutic modalities for phantom limb pain: a scoping review.

East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan·2025
Same author

Assessment of HNA alloimmunisation risk in Northeastern Thais, Burmese and Karen.

Transfusion medicine (Oxford, England)·2017
Same author

Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.

Transfusion medicine (Oxford, England)·2017
Same author

The prevalence of leucocyte alloantibodies in blood donors from South China.

Transfusion medicine (Oxford, England)·2016
Same author

Two cases of platelet transfusion refractoriness and one case of possible FNAIT caused by antibodies against CD36 in China.

Transfusion medicine (Oxford, England)·2014
Same journal

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same journal

Systematic review of clinical evidence for Kneipp medicine.

Wiener klinische Wochenschrift·2026
Same journal

Pelvic resections in primary sarcomas : Surgical outcomes and survival analysis of 75 patients.

Wiener klinische Wochenschrift·2026
Same journal

Jungmediziner*innen am Start: 11. Workshop für den medizinischen Nachwuchs.

Wiener klinische Wochenschrift·2026
Same journal

Stellungnahme der ÖGP zur geplanten Gesetzesnovelle zum Nichtraucherschutzgesetz.

Wiener klinische Wochenschrift·2026
Same journal

MUW researcher of the month: Dr. Moritz Schaefer.

Wiener klinische Wochenschrift·2026
See all related articles

Alloantibodies targeting human platelet antigens cause various transfusion reactions and conditions like neonatal alloimmune thrombocytopenia. Current diagnostic methods are effective, with future innovations promising enhanced detection.

Area of Science:

  • Immunology
  • Transfusion Medicine
  • Hematology

Background:

  • Alloantibodies against human platelet membrane alloantigens cause significant clinical syndromes.
  • Conditions include neonatal alloimmune thrombocytopenia (NAIT), post-transfusion purpura (PTP), and platelet transfusion refractoriness (PTR).
  • Alloimmune reactions involving platelets are also observed after hematopoietic stem cell transplantation.

Purpose of the Study:

  • To review the mechanisms and clinical significance of antibody formation against platelet alloantigens.
  • To discuss the classification of platelet alloantigens (Type I and Type II) and their associated clinical conditions.
  • To outline current diagnostic methods and future prospects for platelet antibody detection.

Main Methods:

  • Review of existing literature on platelet alloantigens and alloimmunization.

Related Experiment Videos

  • Discussion of molecular basis of platelet specific alloantigens, including mutations and glycoprotein conformation.
  • Description of diagnostic assays such as MAIPA and immunobead assays.

    • Main Results:

    • Type I alloantigens (ABO, HLA class I) are involved in PTR and febrile nonhemolytic transfusion reactions.
    • Type II alloantigens are implicated in NAIT, PTP, and passive alloimmune thrombocytopenia.
    • Platelet antigen expression varies, and many determinants rely on glycoprotein conformation rather than single mutations.

    Conclusions:

    • Understanding platelet alloantigens is crucial for managing transfusion reactions and related conditions.
    • Current diagnostic assays are established, but advancements in phage display and recombinant antigens are expected to improve phenotyping and antibody detection.
    • Further research into the complex nature of platelet alloantigens will enhance clinical management and patient outcomes.